Overview

Open-Label Treatment Extension Study

Status:
Completed

Trial end date:
2017-08-23

Target enrollment:

Participant gender:

Summary

Study is to provide ongoing treatment with RBP-6000 and safety monitoring for subjects who complete the RB-US-13-0003 study (NCT02510014) and for whom a new treatment venue has not been identified or arranged.

Phase:

Phase 3

Details

Lead Sponsor:

Indivior Inc.

Treatments:

Buprenorphine